An observational study in Reumatoid Arthritis, Corticosteroids Adverse Reaction and Adrenal Insufficiency, sponsored by Bursa Yuksek Ihtisas Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Bursa Yuksek Ihtisas Training and Research Hospital · Observational
This study aims to investigate the prevalence of adrenal insufficiency in rheumatoid arthritis (RA) patients receiving low-dose corticosteroid therapy and to identify the factors influencing adrenal insufficiency. To this end, the researchers plan to conduct a study comparing the prevalence of adrenal insufficiency and associated factors among RA patients-who are currently receiving low-dose corticosteroid therapy during outpatient follow-up and have consented to participate-by categorizing them into three groups based on the duration of treatment: short (3 weeks-3 months), medium (3-12 months), and long (>12 months).
Although corticosteroids are used as "bridge therapy" in the treatment of rheumatoid arthritis (RA), many patients continue on low-dose corticosteroid regimens. Prolonged high-dose corticosteroid therapy can lead to permanent adrenal insufficiency, a fact well-documented in the literature. The human body produces the equivalent of 5-7.5 mg of prednisolone daily; however, data regarding the frequency of adrenal insufficiency associated with the use of therapeutic corticosteroid doses below this endogenous production level are limited. This study aims to investigate the presence of adrenal insufficiency-in accordance with guideline recommendations-among rheumatoid arthritis patients undergoing low-dose corticosteroid therapy (defined as doses not exceeding the equivalent of 5 mg of prednisolone) for short (3 weeks to 3 months), medium (3 to 12 months), and long (more than 12 months) durations. This study also aims to investigate the factors contributing to the development of adrenal insufficiency in rheumatoid arthritis (RA) patients receiving short-, medium-, and long-term corticosteroid therapy.
133 studies on the registry are indexed under Adrenal Insufficiency; 27 are open to participants now.
This study's planned enrollment of 120 is above the median of 76 across 57 observational studies indexed under Adrenal Insufficiency.
Browse Adrenal Insufficiency studies →Bursa Yuksek Ihtisas Training and Research Hospital is the lead sponsor of 46 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will be selected from RA patients followed at the Rheumatology Clinic of Bursa Yuksek Ihtisas Training and Research Hospital.
Exclusion Criteria:
low-duration corticosteroid
Diagnostic Test: ACTH stimulation test · Diagnostic Test: Cortisol
medium-duration corticosteroid
Diagnostic Test: ACTH stimulation test · Diagnostic Test: Cortisol
long-duration corticosteroid
Diagnostic Test: ACTH stimulation test · Diagnostic Test: Cortisol
ACTH stimulation test with 250 micrograms tetracosactide acetate if plasma cortisole is below 10 mcg/dl
morning fasting plasma cortisol
prevalence of adrenal insufficiency
The assessment of adrenal insufficiency is conducted in two stages: the morning cortisol level is measured in the first stage, and the ACTH stimulation test is administered to the relevant participants in the second stage.
Time frame: through study completion, an average of 1 year
DAS-28
Disease activity score for rheumatoid arthritis
Time frame: through study completion, an average of 1 year
HAQ
Health Assessment Questionnaires
Time frame: through study completion, an average of 1 year
RAPİD-3
Routine Assessment of Patient Index Data 3
Time frame: through study completion, an average of 1 year
PASI
Psoriasis Area Severity Index
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bursa Yuksek Ihtisas Training and Research Hospital